Regarding the role of miR-4458 in NSCLC immunotherapy, Liu et al. [117] found that in NSCLC patients, PD-L1 expression is elevated, in contrast with decreasing miR-4458 levels, leading to increased cell proliferation and tumor growth [117]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.